JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2008; 52:644-651, doi:10.1016/j.jacc.2008.05.022 (Published online 23 June 2008).
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Supplemental Table
Right arrow All Versions of this Article:
j.jacc.2008.05.022v1
52/8/644    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Sehnert, A. J.
Right arrow Articles by Kraus, W. E.
PubMed
Right arrow Articles by Sehnert, A. J.
Right arrow Articles by Kraus, W. E.
Related Collections
Right arrowRelated Articles

EXPEDITED PUBLICATION

Lack of Association Between Adrenergic Receptor Genotypes and Survival in Heart Failure Patients Treated With Carvedilol or Metoprolol

Amy J. Sehnert, MD*,*, Susan E. Daniels, PhD*, Michael Elashoff, PhD*, James A. Wingrove, PhD*, Christopher R. Burrow, MD*, Benjamin Horne, PhD{dagger}, Joseph B. Muhlestein, MD, FACC{dagger}, Mark Donahue, MD{ddagger}, Stephen B. Liggett, MD§, Jeffrey L. Anderson, MD, FACC{dagger} and William E. Kraus, MD, FACC{ddagger}

* CardioDx, Inc., Palo Alto, California
{dagger} Departments of Cardiology and Cardiovascular Research, Intermountain Medical Center, University of Utah, Salt Lake City, Utah
{ddagger} Department of Medicine and Cardiology, Duke University Medical Center, Durham, North Carolina
§ Departments of Medicine and Physiology, University of Maryland School of Medicine, Baltimore, Maryland

Manuscript received February 7, 2008; revised manuscript received April 29, 2008, accepted May 5, 2008.

* Reprint requests and correspondence: Dr. Amy J. Sehnert, CardioDx, Inc., 2500 Faber Place, Palo Alto, California 94303 (Email: asehnert{at}cardiodx.com).

Objectives: This study investigated the role of adrenergic receptor genetics on transplant-free survival in heart failure (HF).

Background: Discordant results exist for genetic associations between adrenergic receptor alleles and end points of beta-blocker response in HF patients.

Methods: We identified 637 patients enrolled in 2 U.S. cardiovascular genetic registries with HF and left ventricular systolic dysfunction who were discharged on beta-blocker, angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB), and diuretic medications. End points were determined through the national Social Security Death Master File and transplant records. We genotyped 5 polymorphisms in 3 genes: ADRB1 (S49G, R389G), ADRB2 (G16R, Q27E), and ADRA2C (Del322-325) using 5' nuclease assays and performed a multivariable clinical-genetic analysis.

Results: A total of 190 events (29.8%) occurred over a median follow-up of 1,070 days. Multivariable analysis showed a significant effect of 4 clinical factors on survival: age (p = 0.006), gender (p = 0.005), ejection fraction (p = 0.0002), and hemoglobin (p = 0.00010). There was no significant effect of the polymorphisms or haplotypes analyzed on survival.

Conclusions: Genotypes and haplotypes of ADRB1, ADRB2, and ADRA2C did not significantly affect survival in metoprolol-treated or carvedilol-treated HF patients in this study. These results complement the findings of 2 similarly designed previous studies, but do not replicate an association of ADRB2 haplotypes and survival. All 3 studies differ from a survival benefit reported for bucindolol-treated homozygous ADRB1 R389 individuals. This may be attributable to a drug-specific interaction between genotype and outcome with bucindolol that does not seem to occur with metoprolol or carvedilol.

Key Words: heart failure • genetics • adrenergic receptors • beta-blockers • haplotypes

Abbreviations and Acronyms
  ACEI = angiotensin-converting enzyme inhibitor
  AR = adrenergic receptor
  ARB = angiotensin II receptor blocker
  CI = confidence interval
  EF = ejection fraction
  HF = heart failure
  HR = hazard ratio
  ICD = implantable cardioverter-defibrillator
  LV = left ventricle/ventricular
  LVEF = left ventricular ejection fraction
  NYHA = New York Heart Association
  SNP = single-nucleotide polymorphism


Related Articles

Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 52: A29-A30. [Full Text] [PDF]

Pharmacogenomics and the Failing Heart: Are We Waiting for Godot?
Douglas L. Mann and Dennis M. McNamara
J. Am. Coll. Cardiol. 2008 52: 652-654. [Full Text] [PDF]



This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
D. L. Mann and D. M. McNamara
Pharmacogenomics and the Failing Heart: Are We Waiting for Godot?
J. Am. Coll. Cardiol., August 19, 2008; 52(8): 652 - 654.
[Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2008 by the American College of Cardiology Foundation.